Tislelizumab meets primary endpoint in Phase III oesophageal cancer trial

Phase III RATIONALE 302 trial showed that tislelizumab (a PD-1 inhibitor) improved overall survival vs chemotherapy (median 8.6 vs. 6.3 months; HR=0.70, 95% CI: 0.57-0.85) in patients with unresectable recurrent locally advanced or metastatic oesophageal squamous cell carcinoma.

Biospace Inc.